Melanotropic peptides: More than just 'Barbie drugs' and 'sun-tan jabs'?

British Journal of Dermatology

Volumn 163, Issue 3, 2010, Pages 451-455

  Langan, E A ^a   Nie, Z ^a   Rhodes, L E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

melanocyte stimulating hormone analogues; melanotan; moles; photoprotection; photosensitivity disorders; tanning

Indexed keywords

AFAMELANOTIDE; ALPHA INTERMEDIN; ALPHA INTERMEDIN DERIVATIVE; DERMATOLOGICAL AGENT; MELANOTAN II; SCENESSE; UNCLASSIFIED DRUG;

AWARENESS; CLINICAL FEATURE; DISEASE TRANSMISSION; DNA DAMAGE; DRUG SELF ADMINISTRATION; HUMAN; INTERNET; MELANOGENESIS; NEVUS; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SUNBURN; ULTRAVIOLET RADIATION;

ALPHA-MSH; CLINICAL TRIALS AS TOPIC; HUMANS; INJECTIONS, SUBCUTANEOUS; SKIN DISEASES; SKIN PIGMENTATION; SUNSCREENING AGENTS;

EID: 77955889534     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09891.x     Document Type: Review

References (37)

1. Mahne C. Implant Offers Tanning Revolution. 2002. Available at: http://news.bbc.co.uk/1/hi/health/2231991.stm (last accessed 7 June 2010).
2. Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ 2009 338:b556.
3. Medicines and Healthcare products Regulatory Agency (MHRA). Press Release: 'Tan-jab' is an Unlicensed Medicine and may not be Safe - Warns Medicines Regulator. 2008. Available at: http://www.mhra.gov.uk/NewsCentre/ Pressreleases/CON031009 (last accessed 7 June 2010).
4. Eller MS, Ostrom K, Gilchrest BA. DNA damage enhances melanogenesis. Proc Natl Acad Sci USA 1996 93:1087 1092.
5. Cui R, Widlund HR, Fiege E et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007 128:853 864.
6. Miller AJ, Tsao H. New insights into pigmentary pathways and skin cancer. Br J Dermatol 2010 162:22 8.
7. Park HY, Kosmadaki M, Yaar M, Gilchrest BA. Cellular mechanisms regulating human melanogenesis. Cell Mol Life Sci 2009 66:1493 1506.
8. Sawyer TK, Sanfilippo PJ, Hruby VJ et al. 4-Norleucine, 7-d-phenylalanine-alpha-melanocyte stimulating hormone: a highly potent alpha melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980 77:5754 5758.
9. 7]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides 2006 27:388 394.
10. Schallreuter KU, Kothari S, Chavan B, Spencer JD. Regulation of melanogenesis - controversies and new concepts. Exp Dermatol 2008 17:395 404.
11. Dorr RT, Lines R, Levine N et al. Evaluation of melanotan-2, a superpotent cyclic melanotropic peptide in a pilot phase-1 clinical trial. Life Sci 1996 58:1777 1784.
12. Grabbe S, Bhardwaj RS, Mahnke K et al. alpha-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. J Immunol 1996 156:473 478.
13. Maaser C, Kannengiesser K, Kucharzik T. Role of the melanocortin system in inflammation. Ann NY Acad Sci 2006 1072:123 134.
14. Loser K, Brzoska T, Oji V et al. The neuropeptide alpha-melanocyte- stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans. PLoS ONE 2010 5:e8958.
15. Brzoska T, Luger TA, Maaser C et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008 29:581 602.
16. Song X, Mosby N, Yang J et al. alpha-MSH activates immediate defense responses to UV-induced oxidative stress in human melanocytes. Pigment Cell Melanoma Res 2009 22:809 818.
17. Levine N, Sheftel SN, Eytan T et al. Induction of tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA 1991 226:2730 2736.
18. 7]-MSH in humans. Photochem Photobiol 2000 72:526 532.
19. 7]-MSH increases the eumelanin: phaeomelanin ratio in cultured human melanocytes. J Invest Dermatol 1995 104:83 5.
20. 7]-alpha-melanocyte stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned caucasian volunteers. J Invest Dermatol 2006 126:1869 1878.
21. Dorr RT, Ertl G, Levine N et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol 2004 140:827 835.
22. Clinuvel Pharmaceuticals Ltd. Home page. Available at: http://www.clinuvel.com (last accessed 7 June 2010).
23. Jong CT, Finlay AY, Pearse AD et al. The quality of life of 790 patients with photodermatoses. Br J Dermatol 2008 159:192 197.
24. Ling TC, Richards HL, Janssens AS et al. Seasonal and latitudinal impact of polymorphic light eruption on quality of life. J Invest Dermatol 2006 126:1648 1651.
25. Minder EI, Schneider-Yin X, Steurer J, Bachmann LM. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol 2009 55:84 97.
26. Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonist analog of -melanocyte stimulating hormone. Photochem Photobiol 2009 85:1434 1439.
27. Botto NC, Warshaw EM. Solar urticaria. J Am Acad Dermatol 2008 59:909 920.
28. Richards HL, Ling TC, Evangelou G et al. Evidence of high levels of anxiety and depression in polymorphic light eruption and their association with clinical and demographic variables. Br J Dermatol 2008 159:439 444.
29. Langan EA, Ramlogan D, Jamieson LA, Rhodes LE. Change in moles linked to use of unlicensed 'sun tan jab'. BMJ 2009 338:b277.
30. Cardones AR, Grichnik JM. Alpha melanocyte stimulating hormone-induced eruptive nevi. Arch Dermatol 2009 5:219 223.
31. Cousen P, Colver G, Helbling I. Eruptive melanocytic naevi following melanotan injection. Br J Dermatol 2009 161:707 708.
32. Ellis R, Kirkham N, Seukeran D. Malignant melanoma in a user of melanotan I. Br Med J 2009 Rapid Responses. Available at: http://www.bmj.com/cgi/ eletters/338/feb17-2/b566#209418 (last accessed 7 June 2010).
33. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historic milestones, clinical studies and commercialization. Peptides 2006 27:921 930.
34. 7]-MSH, stimulates human tyrosinase activity and inhibits cell proliferation. Pigment Cell Res 1995 8:314 323.
35. Abdel-Malek ZA, Kadekaro AL, Kavanagh RJ et al. Melanoma prevention strategy based on using tetrapeptide -MSH analogues that protect human melanocytes from UV induced DNA damage and cytotoxicity. FASEB J 2006 20:1561 1563.
36. Abdel-Malek ZA, Ruwe A, Kavanagh-Starner R et al. alpha-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes. Pigment Cell Melanoma Res 2009 22:635 644.
37. Seiffert K, Granstein RD. Neuropeptides and neuroendocrine hormones in ultraviolet radiation-induced immunosuppression. Methods 2002 28:97 103.